BRISTOL-MYERS SQUIBB COMPANY Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate of 4.20% for the 9-month period ending 2015-09-30, per its 10-Q filed 2015-10-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate · last filed 2015-10-27
- BRISTOL-MYERS SQUIBB COMPANY defined benefit plan, assumptions used calculating net periodic benefit cost, discount rate for the quarter ending 2015-03-31 was 3.60%, a 14.29% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY defined benefit plan, assumptions used calculating net periodic benefit cost, discount rate for the quarter ending 2014-03-31 was 4.20%.
| Period end | Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate 3 month | Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate 6 month | Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate 9 month | Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate 12 month |
|---|---|---|---|---|
| 2015-09-30 | 4.20% 10-Q · filed 2015-10-27 | |||
| 2015-06-30 | 4.30% 10-Q · filed 2015-07-23 | |||
| 2015-03-31 | 3.60% 10-Q · filed 2015-04-28 | |||
| 2014-12-31 | 3.80% 10-Q · filed 2015-10-27 | |||
| 2014-09-30 | 4.10% 10-Q · filed 2014-10-24 | |||
| 2014-06-30 | 4.00% 10-Q · filed 2014-07-24 | |||
| 2014-03-31 | 4.20% 10-Q · filed 2014-04-29 | |||
| 2013-12-31 | 4.60% 10-Q · filed 2014-10-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |